Delivery Order SPE2DB20D3101-SPE2DB25FRWV4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $25,982.33 on August 21, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp valued at $59,873.00 for the supply of Dupixent 300 mg/2 ml pen injectors on September 26, 2025. This firm fixed price, competitively awarded delivery order is scheduled for completion by September 29, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,699.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with completion scheduled for September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency awarded a delivery order valued at $54,946.51 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 3, 2025, with an ultimate completion date of July 7, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a contract ceiling value of $44,612.34. This firm fixed-price delivery order, with an ultimate completion date of September 18, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $54,265.48 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded procurement under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $4,630.35 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $109,423.55 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $44,168.03 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on May 30, 2025, with completion scheduled for June 2, 2025. This delivery order represents a non-competitive, non-set-aside award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The IDC, valued at $999,999,999 and running through December 2026, serves as a...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWV4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $350,241.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This firm fixed-price delivery order, issued on September 27, 2025, is set to be completed by September 29, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical supply requirements through open competition. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. The IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs. Dupixent, a specialty medication used primarily for inflammatory conditions, falls within the broader therapeutic portfolio that AmerisourceBergen provides to federal healthcare customers including the Defense Health Agency and U.S. Coast Guard through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $350.2k | 9/27/25 |